Avidity Biosciences Sets February 12 Record Date for Spin-Off Ahead of Novartis Acquisition

summarizeSummary

Avidity Biosciences announced the expected record date of February 12, 2026, for the pro rata distribution of Atrium Therapeutics, Inc. (SpinCo) shares to its stockholders, a key step in its proposed acquisition by Novartis AG.

check_boxKey Events

• Spin-Off Record Date Set

  Avidity Biosciences has designated February 12, 2026, as the record date for the pro rata distribution of Atrium Therapeutics, Inc. (SpinCo) shares.

• Spin-Off Distribution Ratio

  Stockholders will receive one share of SpinCo common stock for every ten shares of Avidity common stock held on the record date.

• Part of Novartis Acquisition

  This spin-off is a component of the previously announced proposed acquisition of Avidity Biosciences by Novartis AG.

• Transaction Progress

  The announcement of the record date signifies a material step forward in the execution of the merger and spin-off, following the definitive proxy statement filed on January 30, 2026.

auto_awesomeAnalysis

This filing provides a key operational update regarding the previously announced acquisition by Novartis AG and the concurrent spin-off of Atrium Therapeutics, Inc. (SpinCo). The designation of a record date for the spin-off is a concrete step towards the completion of these significant corporate transactions, indicating progress in the deal's execution. Investors should note the 1-for-10 share distribution ratio for SpinCo common stock. The overall transaction, including the spin-off, remains subject to shareholder approval and other closing conditions.